The National Comprehensive Cancer Network (NCCN) is expected to convene an emergency panel review on Wednesday after the FDA's Monday approval of AstraZeneca's Imfinzi (durvalumab) in combination with BCG for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) — the first immunotherapy combination to receive US clearance for this indication. Urologic oncology specialists at major cancer centres including MD Anderson, Memorial Sloan Kettering, and Johns Hopkins have begun circulating internal memos outlining how the approval may reshape first-line treatment protocols for an estimated 80,000 newly diagnosed NMIBC patients annually in the United States.

The FDA approval, announced Tuesday, was based on data from the Phase III POTOMAC trial, which demonstrated that durvalumab plus BCG induction and maintenance significantly improved disease-free survival compared with BCG alone in patients who had not previously received BCG therapy. The approval represents a landmark shift in a disease area where BCG monotherapy has been the standard of care for decades with limited innovation.

AstraZeneca's oncology team in Wilmington, Delaware confirmed Wednesday morning that it has already submitted the labelling data package to major US payers and is in active discussions with the Centers for Medicare and Medicaid Services (CMS) regarding reimbursement classification. The company expects commercial availability within 30 days, with an initial focus on academic medical centres that participated in the POTOMAC trial network.

The American Urological Association (AUA), whose annual meeting concluded last month, issued a statement Wednesday indicating it will publish an interim clinical guidance document by the end of June to help community urologists integrate the new combination regimen into practice. 'This approval addresses a genuine unmet need,' said the AUA's chief science officer in a prepared statement. 'We want to ensure that clinicians in community settings have practical, evidence-based guidance as quickly as possible.'

Analysts at Jefferies and Bernstein raised their Imfinzi revenue forecasts for fiscal year 2027 on Wednesday, citing the NMIBC approval as an underappreciated growth driver alongside Imfinzi's existing lung and biliary tract indications. AstraZeneca shares rose modestly in London trading as the market absorbed the implications of what executives described as a 'significant expansion of Imfinzi's addressable patient population' in the United States.